PINL:GRPOF - Post by User
Comment by
lscfaon Apr 23, 2021 7:36pm
109 Views
Post# 33060178
RE:RE:RE:RE:video interview
RE:RE:RE:RE:video interview Synthetic thc/CBD is still the way to go.
Nov 25, 2019 - QIXLEEF is the company’s first-generation cannabinoid therapeutic in development for treating advanced cancer patients with uncontrolled pain. The company believes a subset of the advanced cancer patient population prefers to consume cannabis in the traditional way, using dried flower bud as a drug product. In early 2019, Tetra uncovered an impurity in the dried flower bud cannabis and worked diligently to find solutions to develop a pharmaceutical grade cannabis drug free of any traces of the impurity.
MiningGospel wrote: There's something called the Entourage effect, where CBD +THC + Terpenes work in conjunction with each other to help with pain relief. Rafi Mechoulum has done a lot of work in this field
lscfa wrote: More confusion:
CAUMZ is a synthetic drug and QIXLEEF is a plant-based drug. Why?
QIXLEEF has a fixed ratio of cbd:thc. What is CAUMZ mimicking as a synthetic?
Why not make QIXLEEF synthetically to ensure a fixed ratio? Can a grower (Aphria) really guarantee consistency with tight tolerances?
lscfa wrote: Interviewer asked what is it that investors are not getting? Part of the answer is confusion on whether Tetra is a cannabis stock or a biotech stock. I would add there is confusion on what is difference between CAUMZ and QIXLEEF. Are they both synthetic cannabis drugs? If so, why is Aphria the manufacturer? Does Aphria make synthetic cannabinoids?